Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
Loupakis F, Sharma S, Derouazi M, Murgioni S, Biason P, Rizzato MD, Rasola C, Renner D, Shchegrova S, Koyen Malashevich A, Malhotra M, Sethi H, Zimmermann BG, Aleshin A, Moshkevich S, Billings PR, Sedgwick JD, Schirripa M, Munari G, Cillo U, Pilati P, Dei Tos AP, Zagonel V, Lonardi S, Fassan M. Loupakis F, et al. Among authors: zagonel v. JCO Precis Oncol. 2021 Jul 21;5:PO.21.00101. doi: 10.1200/PO.21.00101. eCollection 2021 Jul. JCO Precis Oncol. 2021. PMID: 34327297 Free PMC article.
Hepatoid adenocarcinoma of the colon: what should we target?
Cappetta A, Bergamo F, Mescoli C, Lonardi S, Rugge M, Zagonel V. Cappetta A, et al. Among authors: zagonel v. Pathol Oncol Res. 2012 Jan;18(1):93-6. doi: 10.1007/s12253-011-9424-5. Epub 2011 Jun 12. Pathol Oncol Res. 2012. PMID: 21667305 Free article.
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E. Loupakis F, et al. Among authors: zagonel v. Cancer. 2012 Mar 15;118(6):1523-32. doi: 10.1002/cncr.26460. Epub 2011 Aug 25. Cancer. 2012. PMID: 22009364 Free article.
Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, Fiocca R, Rugge M. Fassan M, et al. Among authors: zagonel v. Histopathology. 2012 Nov;61(5):769-76. doi: 10.1111/j.1365-2559.2012.04272.x. Epub 2012 Aug 9. Histopathology. 2012. PMID: 22882541
The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples.
Grillo F, Fassan M, Ceccaroli C, Giacometti C, Curto M, Zagonel V, Ceppa P, Nitti D, Castoro C, Fiocca R, Rugge M, Mastracci L. Grillo F, et al. Among authors: zagonel v. Transl Oncol. 2013 Feb;6(1):10-6. doi: 10.1593/tlo.12334. Epub 2013 Feb 1. Transl Oncol. 2013. PMID: 23418612 Free PMC article.
The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V, Castoro C, Mastracci L, Farinati F, Nitti D, Zaninotto G, Rugge M. Fassan M, et al. Among authors: zagonel v. Hum Pathol. 2013 Sep;44(9):1804-10. doi: 10.1016/j.humpath.2013.01.023. Epub 2013 Apr 22. Hum Pathol. 2013. PMID: 23618359
Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.
Brunello A, Fontana A, Zafferri V, Panza F, Fiduccia P, Basso U, Copetti M, Lonardi S, Roma A, Falci C, Monfardini S, Cella A, Pilotto A, Zagonel V. Brunello A, et al. Among authors: zagonel v. J Cancer Res Clin Oncol. 2016 May;142(5):1069-77. doi: 10.1007/s00432-015-2088-x. Epub 2016 Jan 12. J Cancer Res Clin Oncol. 2016. PMID: 26758276 Free PMC article.
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Sartore-Bianchi A, et al. Among authors: zagonel v. Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Lancet Oncol. 2016. PMID: 27108243 Free article. Clinical Trial.
447 results